Role of gut microbiota and metabolomics in the lipid-lowering efficacy of statins among Chinese patients with coronary heart disease and hypercholesterolemia
Frontiers in Cellular and Infection Microbiology · 2024
DOI: 10.3389/fcimb.2024.1408581 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2024. Verfasst von Lihua Hu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Coronary Disease, Gastrointestinal Microbiome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypercholesterolemia. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China.
Abstract (Originalsprache)
Background
Statins, being the primary pharmacological intervention for hypercholesterolemia, exhibit a notable degree of interpatient variability in their effectiveness, which may be associated with gut microbiota. This study sought to identify the biomarkers for evaluating differences in statin efficacy.
Methods
A quasi case-control study was conducted among participants with hypercholesterolemia and coronary heart disease taking rosuvastatin essential. According to the level of low density lipoprotein cholesterol (LDL-C), participants was divided into the “Up to standard” (US) group and the “Below standard” (BS) group. 16S rDNA sequencing and untargeted metabolomics were applied to detected the information of gut microbiota and related metabolites.
Results
A total of 8 US and 8 BS group matched by age and sex were included in the final analysis. 16S rDNA sequencing results indicated that the characteristic strains of the US group were f-Eubacterium_coprostanoligenes and g-Papillibacter , while the characteristic flora of the BS group were o-C0119 , g-Pseudolabrys, s-Dyella-Marensis and f-Xanthobacaceae. Metabolomic results suggested that the levels of chenodeoxycholic acid-3-β-D-glucuronide, 1-methylnicotinamide and acetoacetate in stool samples of the US group were significantly higher than those of the BS group. By identifying the differentially abundant bacterial taxa, the gut microbiota could modulate the efficacy of statins through producing enzymes involved in cholesterol metabolism.
Conclusions
The findings suggest that the difference in statin efficacy may be related to gut microbiota strains that can produce short-chain fatty acids and secondary bile acids and affect the efficacy of statins by regulating the activities of cholesterol metabolite-related proteins. Metabolites related to short-chain fatty acids and secondary bile acids in the gut are expected to be biomarkers indicating the efficacy of statins.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Peking University First Hospital, Beijing, China.
- Institute of Cardiovascular Disease, Peking University First Hospital, Beijing, China.
- School of Engineering Medicine of Beihang University and Key Laboratory of Big Data-Based Precision Medicine (Beihang University), Ministry of Industry and Information Technology of China, Beijing, China.
- Department of Occupational and Environmental Health Sciences, School of Public Health, Peking University, Beijing, China.
- State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China.
- National Health Commission (NHC) Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing, China.
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Hu, L., Hu, B., Zhang, L., Hu, Y., Zhang, Y., Zhang, R., Yu, H., Liu, D., Wang, X., Lin, O., Gong, Y., Zhang, Y., Li, C., & Li, J. (2024). Role of gut microbiota and metabolomics in the lipid-lowering efficacy of statins among Chinese patients with coronary heart disease and hypercholesterolemia. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2024.1408581
Vancouver
Hu L, Hu B, Zhang L, Hu Y, Zhang Y, Zhang R, et al. Role of gut microbiota and metabolomics in the lipid-lowering efficacy of statins among Chinese patients with coronary heart disease and hypercholesterolemia. Frontiers in Cellular and Infection Microbiology. 2024. doi:10.3389/fcimb.2024.1408581
BibTeX
@article{Hu2024,
author = {Hu, Lihua and Hu, Boxian and Zhang, Long and Hu, Yuhong and Zhang, Yali and Zhang, Ruihang and Yu, Hongxi and Liu, Dan and Wang, Xiaolei and Lin, Ouya and Gong, Yanjun and Zhang, Yan and Li, Cheng and Li, Jianping},
title = {Role of gut microbiota and metabolomics in the lipid-lowering efficacy of statins among Chinese patients with coronary heart disease and hypercholesterolemia},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2024},
doi = {10.3389/fcimb.2024.1408581}
}
EUVIMED